Nutritional considerations with antiobesity medications

被引:13
|
作者
Almandoz, Jaime P. [1 ]
Wadden, Thomas A. [2 ]
Tewksbury, Colleen [3 ]
Apovian, Caroline M. [4 ]
Fitch, Angela [5 ]
Ard, Jamy D. [6 ,7 ]
Li, Zhaoping [8 ]
Richards, Jesse [9 ]
Butsch, W. Scott [10 ]
Jouravskaya, Irina [11 ]
Vanderman, Kadie S. [12 ]
Neff, Lisa M. [11 ,13 ]
机构
[1] Univ Texas, Southwestern Med Ctr, Div Endocrinol, Dallas, TX USA
[2] Univ Penn, Dept Psychiat, Philadelphia, PA USA
[3] Univ Penn, Dept Surg, Philadelphia, PA USA
[4] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA USA
[5] Knownwell, Boston, MA USA
[6] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA
[7] Wake Forest Sch Med, Dept Med, Winston Salem, NC USA
[8] Univ Calif Los Angeles, Ctr Human Nutr, Los Angeles, CA USA
[9] Univ Oklahoma, Sch Med, Dept Internal Med, Tulsa, OK USA
[10] Cleveland Clin, Bariatr & Metab Inst, Cleveland, OH USA
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Syneos Hlth, Morrisville, NC USA
[13] Eli Lilly & Co, Lilly Corp Ctr, Global Med Affairs Obes, Indianapolis, IN 46225 USA
关键词
PEPTIDE-1 RECEPTOR AGONISTS; CARDIOVASCULAR RISK-FACTORS; LONG-TERM PERSISTENCE; BINGE-EATING DISORDER; WEIGHT-LOSS; CLINICAL-PRACTICE; AMERICAN ASSOCIATION; PRACTICE GUIDELINES; OBESITY MANAGEMENT; FOOD-INTAKE;
D O I
10.1002/oby.24067
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of >= 15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.
引用
收藏
页码:1613 / 1631
页数:19
相关论文
共 50 条
  • [1] Response to "Nutritional considerations with antiobesity medications"
    Bett, Gabriela de Souza
    Schuelter-Trevisol, Fabiana
    Trevisol, Daisson Jose
    OBESITY, 2024, 32 (11) : 1981 - 1981
  • [2] Response to "Nutritional considerations with antiobesity medications"
    Athinarayanan, Shaminie J.
    OBESITY, 2025, 33 (01) : 7 - 8
  • [3] Net prices of new antiobesity medications
    Hernandez, Inmaculada
    Sullivan, Sean D.
    OBESITY, 2024, 32 (03) : 472 - 475
  • [4] Physical activity in the new era of antiobesity medications
    Jakicic, John M.
    Rogers, Renee J.
    Church, Timothy S.
    OBESITY, 2024, 32 (02) : 234 - 236
  • [5] A Prescription for Achieving Equitable Access to Antiobesity Medications
    Wright, Davene R.
    Guo, Jingchuan
    Hernandez, Inmaculada
    JAMA HEALTH FORUM, 2023, 4 (04):
  • [6] State Coverage and Reimbursement of Antiobesity Medications in Medicaid
    Liu, Benjamin Y.
    Rome, Benjamin N.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (14): : 1230 - 1232
  • [7] PERCEPTIONS OF ANTIOBESITY MEDICATIONS AMONG PERSONAL TRAINERS
    Lobb, Linda R.
    Lobb, William B.
    Hallam, Jeffrey S.
    JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, 2008, 22 (02) : 485 - 489
  • [8] The Societal Value of Broader Access to Antiobesity Medications
    Kabiri, Mina
    Ward, Alison Sexton
    Ramasamy, Abhilasha
    van Eijndhoven, Emma
    Ganguly, Rahul
    Smolarz, B. Gabriel
    Zvenyach, Tracy
    Goldman, Dana P.
    Baumgardner, James R.
    OBESITY, 2020, 28 (02) : 429 - 436
  • [9] Timing the Discussion of Antiobesity Medications During Obesity Treatment
    Rebello, Candida J.
    O'Neil, Patrick M.
    Horn, Deborah B.
    Greenway, Frank L.
    OBESITY, 2016, 24 (10) : 2027 - 2028
  • [10] Real-world primary nonadherence to antiobesity medications
    Kan, Hong
    Bae, Jay P.
    Dunn, Julia P.
    Buysman, Erin K.
    Gronroos, Noelle N.
    Swindle, Jason P.
    Bengtson, Lindsay G. S.
    Ahmad, Nadia
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2023, 29 (10): : 1099 - 1108